Compare PZG & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PZG | LUNG |
|---|---|---|
| Founded | 1992 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Industrial Specialties |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 113.8M | 97.1M |
| IPO Year | 2015 | 2020 |
| Metric | PZG | LUNG |
|---|---|---|
| Price | $1.23 | $1.92 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $3.40 |
| AVG Volume (30 Days) | ★ 265.1K | 255.6K |
| Earning Date | 09-17-2026 | 10-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 7.64 |
| EPS | ★ N/A | N/A |
| Revenue | $330,259.00 | ★ $90,497,000.00 |
| Revenue This Year | N/A | $0.06 |
| Revenue Next Year | N/A | $8.58 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 8.01 |
| 52 Week Low | $0.95 | $1.13 |
| 52 Week High | $2.70 | $2.89 |
| Indicator | PZG | LUNG |
|---|---|---|
| Relative Strength Index (RSI) | 36.94 | 44.84 |
| Support Level | $1.07 | $1.20 |
| Resistance Level | $1.26 | $2.12 |
| Average True Range (ATR) | 0.06 | 0.10 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 15.00 | 36.65 |
Paramount Gold Nevada Corp is an exploration-stage mining company. Together with its subsidiaries, the company is engaged in the business of acquiring, exploring, and developing precious metal projects in the United States. Also, it explores for gold and silver. The company enhances the value of projects by implementing exploration and engineering programs that are likely to expand and upgrade known mineralized material to reserves. Its projects include sleeper gold, grassy mountain gold and Bald Peak Project.
Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.